PGx7610: Genetic Evaluation of Hepatotoxicity in Pazopanib Studies (201761)

27/08/2014
29/03/2024
EU PAS number:
EUPAS7361
Study
Finalised
Study identification

EU PAS number

EUPAS7361

Study ID

16369

Official title and acronym

PGx7610: Genetic Evaluation of Hepatotoxicity in Pazopanib Studies (201761)

DARWIN EU® study

No

Study countries

United Kingdom

Study description

No information provided.

Study status

Finalised
Research institutions and networks

Institutions

Contact details

GSK Clinical Disclosure Advisor GSK Clinical Disclosure Advisor Pharma.CDR@gsk.com

Study contact

GSK Clinical Disclosure Advisor GSK Clinical Disclosure Advisor

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

GlaxoSmithKline
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)